|
Managing Drug Interactions in the
Treatment of HIV-Related
Tuberculosis
References
- Burman W, Benator D, Vernon A, et al. Acquired rifamycin resistance with
twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care
Med. Feb 1 2006;173(3):350-356.
- Hung CC, Chen MY, Hsiao CF, Hsieh SM, Sheng WH, Chang SC. Improved outcomes
of HIV-1-infected adults with tuberculosis in the era of highly active antiretroviral
therapy. AIDS. Dec 5 2003;17(18):2615-2622.
- Burman WJ. Issues in the management of HIV-related tuberculosis. Clin
Chest Med. Jun 2005;26(2):283-294.
- Burger DM, Meenhorst PL, Koks CHW, Beijnen JH. Pharmacokinetic interaction
between rifampin and zidovudine. Antimicrob Agents Chemother. 1993;37:1426-1431.
- Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for
treatment of newly diagnosed pulmonary tuberculosis: international multicentre
randomised trial. Lancet. Nov 2 2004;364(9441):1244-1251.
- Okwera A, Whalen C, Byekwaso F, et al. Randomised trial of thiacetazone
and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected
Ugandans. The Makerere University-Case Western University Research Collaboration
[see comments]. Lancet. 1994;344(8933):1323-1328.
- Nettles RE, Mazo D, Alwood K, et al. Risk factors for relapse and acquired
rifamycin resistance after directly observed tuberculosis treatment: a comparison
by HIV serostatus and rifamycin use. Clin Infect Dis. Mar 1 2004;38(5):731-736.
- Acquired rifamycin resistance in persons with advanced HIV disease being
treated for active tuberculosis with intermittent rifamycin-based regimens.
MMWR Morb Mortal Wkly Rep. 2002;51(10):214-215.
- Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers
for Disease Control and Prevention/Infectious Diseases Society of America:
treatment of tuberculosis. Am J Respir Crit Care Med. Feb 15 2003;167(4):603-662.
- Gallicano K, Sahai J, Shukla VK, Cameron DW. Induction of zidovudine glucuronidation
and amination pathways by rifampin in HIV infected patients. Br J Clin
Pharmacol. 1999;48:168-179.
- Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, et al. Pharmacokinetic interactions
between efavirenz and rifampicin in HIV-infected patients with tuberculosis.
Clin Pharmacokinet. 2002;41(9):681-690.
- Manosuthi W, Kiertiburanakul S, Sungkanuparph S, et al. Efavirenz 600 mg/day
versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving
rifampicin: 48 weeks results. AIDS. Jan 2 2006;20(1):131-132.
- Manosuthi W, Sungkanuparph S, Thakkinstian A, et al. Efavirenz levels and
24-week efficacy in HIV-infected patients with tuberculosis receiving highly
active antiretroviral therapy and rifampicin. Aids. Sep 23 2005;19(14):1481-1486.
- Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Vibhagool A. Initiation
of antiretroviral therapy in advanced AIDS with active tuberculosis: clinical
experiences from Thailand. J Infect. Jun 28 2005.
- Patel A, Patel K, Patel J, Shah N, Patel B, Rani S. Safety and antiretroviral
effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral-naive
patients in India who are coinfected with tuberculosis and HIV-1. J Acquir
Immune Defic Syndr. Sep 1 2004;37(1):1166-1169.
- Brennan-Benson P, Lyus R, Harrison T, Pakianathan M, Macallan D. Pharmacokinetic
interactions between efavirenz and rifampicin in the treatment of HIV and
tuberculosis: one size does not fit all. AIDS. Sep 23 2005;19(14):1541-1543.
- Ribera E, Pou L, Lopez RM, et al. Pharmacokinetic interaction between nevirapine
and rifampicin in HIV- infected patients with tuberculosis. J Acquir Immune
Defic Syndr. 2001;28(5):450-453.
- Ramachandran G, Hemanthkumar AK, Rajasekaran S, et al. Increasing nevirapine
dose can overcome reduced bioavailability due to rifampicin coadministration.
J Acquir Immune Defic Syndr. May 2006;42(1):36-41.
- Autar RS, Wit FW, Sankote J, et al. Nevirapine plasma concentrations and
concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis.
Antivir Ther. 2005;10(8):937-943.
- Van Cutsem G, Cohen K, Bedelu M, et al. TB/HIV co-infected patients on rifampin
containing treatment have equivalent ART treatment outcomes, and concurrent
use of nevirapine is not associated with increased hepatoxicity. Paper presented
at: 3rd IAS Conference on HIV Pathogenesis and Treatment; July 24-27, 2005;
Rio de Janiero.
- Avihingsanon A, Manosuthi W, Kantipong P, et al. Pharmacokinetics and 12
weeks efficacy of nevirapine, 400 mg vs. 600 mg per day in HIV-infected patients
with active TB receiving rifampicin: a multicenter study. Paper presented
at: 14th Conference on Retroviruses and Opportunistic Infections; February
25-28, 2007; Los Angeles, CA.
- Burman WJ, Gallicano K, Peloquin C. Therapeutic implications of drug interactions
in the treatment of HIV-related tuberculosis. Clin Infect Dis. 1999;28:419-430.
- la Porte CJ, Colbers EP, Bertz R, et al. Pharmacokinetics of adjusted-dose
lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob
Agents Chemother. May 2004;48(5):1553-1560.
- Burger DM, Agarwala S, Child M, Been-Tiktak A, Wang Y, Bertz R. Effect
of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir
in healthy volunteers. Antimicrob Agents Chemother. 2006;50:3336-3342.
- Justesen US, Andersen AB, Klitgaard NA, Brosen K, Gerstoft J, Pedersen
C. Pharmacokinetic interaction between rifampin and the combination of indinavir
and low-dose ritonavir in HIV-infected patients. Clin Infect Dis. Feb
1 2004;38(3):426-429.
- Ribera E, Azuaje C, Lopez RM, et al. Pharmacokinetic interaction between
rifampicin and the once-daily combination of saquinavir and low-dose ritonavir
in HIV-infected patients with tuberculosis. J Antimicrob Chemother. Apr
2007;59(4):690-697.
- Ribera E, Azuaje C, Lopez RM, et al. Once-daily regimen of saquinavir, ritonavir,
didanosine, and lamivudine in HIV-infected patients with standard tuberculosis
therapy (TBQD Study). J Acquir Immune Defic Syndr. Nov 1 2005;40(3):317-323.
- Drug-induced hepatitis with saquinavir/ritonavir + rifampin. AIDS Clin
Care. Mar 2005;17(3):32.
- Burger D. Unexpected high incidence of nausea, vomiting, and asymptomatic
elevations of AST/ALT enzymes in healthy volunteers receiving rifampin + adjusted
doses of lopinavir/ritonavir. 8th International Workshop on Clinical Pharmacology
of HIVTherapy. Budapest; 2007.
- Rolla VC, da Silva Vieira MA, Pereira Pinto D, et al. Safety, efficacy and
pharmacokinetics of ritonavir 400mg/saquinavir 400mg twice daily plus rifampicin
combined therapy in HIV patients with tuberculosis. Clin Drug Investig.
2006;26(8):469-479.
- Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus
efavirenz-containing regimens for the initial treatment of HIV-1 infection.
N Engl J Med. Apr 29 2004;350(18):1850-1861.
- DART Virology Group and Trial Team. Virological response to a triple nucleoside/nucleotide
analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS.
Jun 26 2006;20(10):1391-1399.
- Moyle G, Higgs C, Teague A, et al. An open-label, randomized comparative
pilot study of a single-class quadruple therapy regimen versus a 2-class triple
therapy regimen for individuals initiating antiretroviral therapy. Antivir
Ther. 2006;11(1):73-78.
- Srikantiah P, Walusimbi MN, Kayanja HK, et al. Early virological response
of zidovudine/lamivudine/abacavir for patients co-infected with HIV and tuberculosis
in Uganda. AIDS. Sep 2007;21(14):1972-1974.
-
Pfizer Labs. Maraviroc package insert. (PDF)
- Wang Y, Serradell N, Bolos J, Rosa E. MK-o518. Drugs Fut. 2007;32:118.
- Scholler-Gyure M, Woodlfall B, Debroye C, et al. Pharmacokinetic interaction
between TMC125 and rifabutin. Paper presented at: Annual Meeting of the Infectious
Diseases Society of America; October 12-15, 2006; Toronto.
- Schwander S, Rusch-Gerdes S, Mateega A, et al. A pilot study of antituberculosis
combinations comparing rifabutin with rifampicin in the treatment of HIV-1
associated tuberculosis: a single-blind randomized evaluation in Ugandan patients
with HIV-1 infection and pulmonary tuberculosis. Tubercle Lung Dis. 1995;76:210-218.
- Gonzalez-Montaner LJ, Natal S, Yonchaiyud P, Olliaro P. Rifabutin for the
treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized,
comparative study versus rifampicin. Tubercle Lung Dis. 1994;75:341-347.
- Perucca E, Grimaldi R, Frigo GM, Sardi A, Monig H, Ohnhaus EE. Comparative
effects of rifabutin and rifampicin on hepatic microsomal enzyme activity
in normal subjects. Eur J Clin Pharmacol. 1988;34:595-599.
- Narita M, Stambaugh JJ, Hollender ES, Jones D, Pitchenik AE, Ashkin D. Use
of rifabutin with protease inhibitors for human immunodeficiency virus-infected
patients with tuberculosis. Clin Infect Dis. 2000;30:779-783.
- Sun E, Heath-Chiozzi M, Cameron DW, et al. Concurrent ritonavir and rifabutin
increases risk of rifabutin-associated adverse events. Paper presented at:
XI International Conference on AIDS, 1996; Vancouver, Canada.
- Sarner L, Fakoya A. Acute onset lactic acidosis and pancreatitis in the
third trimester of pregnancy in HIV-1 positive women taking antiretroviral
medication. Sex Transm Infect. Feb 2002;78(1):58-59.
- Leith J, Piliero P, Storfer S, Mayers D, Hinzmann R. Appropriate use of
nevirapine for long-term therapy. J Infect Dis. Aug 1 2005;192(3):545-546.
- Mirochnick M, Capparelli E. Pharmacokinetics of antiretrovirals in pregnant
women. Clin Pharmacokinet. 2004;43(15):1071-1087.
- Nellen JF, Schillevoort I, Wit FW, et al. Nelfinavir plasma concentrations
are low during pregnancy. Clin Infect Dis. Sep 1 2004;39(5):736-740.
- Stek AM, Mirochnick M, Capparelli E, et al. Reduced lopinavir exposure during
pregnancy. Aids. Oct 3 2006;20(15):1931-1939.
- Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy
after a single, peripartum dose of nevirapine. N Engl J Med. Jan 11
2007;356(2):135-147.
- Ren Y, Nuttall J, Egbers C, et al. Plasma concentrations of efavirenz and
lopinavir in children with and without rifampicin-based anti-TB treatment.
Paper presented at: 14th Conference on Retroviruses and Opportunistic Infections;
February 25-28, 2007; Los Angeles, CA.
- Moultrie H, Meyers T. Antiretroviral and anti-TB co-therapy in children
< 3 years in Soweto, South Africa: outcomes in the first 6 months. Paper
presented at: XVI International AIDS Conference; August 13-18, 2006; Toronto.
- World Health Organization. Antiretroviral therapy of HIV infection in infants
and children: toward universal access: WHO Press; 2006:1-152.
- Ren Y, Nuttall JJ, Egbers C, et al. High prevalence of subtherapeutic plasma
concentrations of efavirenz in children. J Acquir Immune Defic Syndr. Jun
1 2007;45(2):133-136.
- McKinney RE, Jr., Rodman J, Hu C, et al. Long-term safety and efficacy of
a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected,
therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group
Protocol P1021. Pediatrics. Aug 2007;120(2):e416-423.
- Funk MB, Notheis G, Schuster T, et al. Effect of first line therapy including
efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected
children. Eur J Med Res. Dec 7 2005;10(12):503-508.
- Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis
as a cause of death in patients co-infected with tuberculosis and HIV in a
rural area of South Africa. Lancet. Nov 4 2006;368(9547):1575-1580.
Last Reviewed: 05/18/2008 Content Source: Division of Tuberculosis Elimination
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
|